Short Interest in Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Decreases By 57.0%

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 27,500 shares, a drop of 57.0% from the February 28th total of 63,900 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 284,400 shares, the days-to-cover ratio is currently 0.1 days.

Oncotelic Therapeutics Trading Up 13.6 %

Shares of OTCMKTS OTLC opened at $0.07 on Friday. The stock has a market cap of $28.44 million, a P/E ratio of -7.00 and a beta of -0.25. The company has a debt-to-equity ratio of 0.28, a current ratio of 0.01 and a quick ratio of 0.01. Oncotelic Therapeutics has a 1 year low of $0.02 and a 1 year high of $0.07. The firm has a 50-day moving average of $0.04 and a 200 day moving average of $0.03.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.